Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

AMGN and VKTX’s products can pose strong competition to Mounjaro/Zepbound and NVO’s Ozempic/Wegovy in the future. Year to date, Novo Nordisk shares have plunged 23.1% compared with the ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

contributed to uncertainties in the future for these drugs. While Novo Nordisk still remains one of the biggest players in the pharma landscape, the company faces competition from rivals like Lilly ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

The deal includes $11 billion upfront to buy the fill-finish sites that Novo Nordisk said will enable “an expansion of the manufacturing capacity at scale and speed, while providing future ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Septerna will also get royalties on any future product sales, The Wall Street Journal reported. Novo Nordisk will pay all the research and development costs for the project. The U.S. biotech ...